Bukwang Pharmaceutical IND부광약품
003000 · KOSPI · ₩003000 · 부광약품
₩3,750▼ ₩5 (0.13%)End-of-day · Oct 28, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 44.5% | 45.8% | 46.4% | 37.4% | 41.6% | 41.5% |
| Operating margin | 5.4% | 7.1% | 1.0% | −29.8% | −0.1% | 3.1% |
| Net margin | 4.1% | 6.3% | −1.6% | −24.9% | −1.3% | −0.5% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +7.2% | +25.4% | +27.1% | −34.0% | +4.6% | — |
| Operating income growth | −17.7% | +775.6% | +104.3% | −16,158.0% | −104.1% | — |
| Net income growth | −30.1% | +575.4% | +91.6% | −1,165.9% | −170.0% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 2.6% | 4.3% | −1.1% | −12.8% | −0.9% | −0.3% |
| Return on assets | 1.8% | 2.9% | −0.9% | −8.3% | −1.1% | −0.7% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 39.7% | 39.7% | 52.9% | 83.1% | 47.5% | 41.9% |
| Net debt to equity | −7.3% | −4.9% | −4.5% | −31.0% | −31.5% | −29.6% |
| Current ratio | 233.2% | 257.3% | 575.6% | 260.6% | 490.4% | 594.9% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Bukwang Pharmaceutical IND / 부광약품 / 003000 / KRX:003000
Source: KRX statistical information